Plasma Adipsin as a Biomarker and Its Implication in Type 2 Diabetes Mellitus

References

• Oguntibeju O. Pathophysiology and Complications of Diabetes Mellitus. BoD–Books on Demand; 2012.
   Google Scholar
• WHO. Classification of Diabetes Mellitus. World Health Organization; 2019:1–40. Licence: CC BY-NC-SA 3.0 IGO 2019.
   Google Scholar
• Wondafrash DZ, Nire’a AT, Tafere GG, Desta DM, Berhe DA, Zewdie KA. Thioredoxin-interacting protein as a novel potential therapeutic target in diabetes mellitus and its underlying complications. Diabetes Metab Syndr Obes. 2020;13:43. doi:10.2147/DMSO.S232221
   PubMed Web of Science ®Google Scholar
• Afroz A, Ali L, Karim MN, et al. Glycaemic control for people with type 2 diabetes mellitus in Bangladesh-an urgent need for optimization of management plan. Sci Rep. 2019;9(1):1–10. doi:10.1038/s41598-019-46766-9
   PubMedGoogle Scholar
• Baynes HW. Classification, pathophysiology, diagnosis and management of diabetes mellitus. J Diabetes Metab. 2015;6(5):1–9.
   Web of Science ®Google Scholar
• ADA. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2014;37(Supplement 1):S81–S90. doi:10.2337/dc14-S081
   PubMed Web of Science ®Google Scholar
• Asmelash D, Asmelash Y. The burden of undiagnosed diabetes mellitus in adult African population: a systematic review and meta-analysis. J Diabetes Res. 2019;2019:1–8. doi:10.1155/2019/4134937
   Web of Science ®Google Scholar
• Fan W. Epidemiology in diabetes mellitus and cardiovascular disease. Cardiovasc Endocrinol. 2017;6(1):8–16. doi:10.1097/XCE.0000000000000116
   PubMedGoogle Scholar
• Piero M, Nzaro G, Njagi J. Diabetes mellitus-a devastating metabolic disorder. Asian J Biomed Pharm Sci. 2015;5(40):1.
   Google Scholar
• Elekofehinti OO, Ejelonu OC, Kamdem JP, Akinlosotu OB, Adanlawo IG. Saponins as adipokines modulator: a possible therapeutic intervention for type 2 diabetes. World J Diabetes. 2017;8(7):337. doi:10.4239/wjd.v8.i7.337
   PubMedGoogle Scholar
• Kohei K. Pathophysiology of type 2 diabetes and its treatment policy. Jpn Med Assoc J. 2010;53(1):41–46.
   Google Scholar
• Zaccardi F, Webb DR, Yates T, Davies MJ. Pathophysiology of type 1 and type 2 diabetes mellitus: a 90-year perspective. Postgrad Med J. 2016;92(1084):63–69. doi:10.1136/postgradmedj-2015-133281
   PubMed Web of Science ®Google Scholar
• Heng L, Comyn O, Peto T, et al. Diabetic retinopathy: pathogenesis, clinical grading, management and future developments. Diabet Med. 2013;30(6):640–650. doi:10.1111/dme.12089
   PubMed Web of Science ®Google Scholar
• Wang W, Lo AC. Diabetic retinopathy: pathophysiology and treatments. Int J Mol Sci. 2018;19(6):1–14.
   Web of Science ®Google Scholar
• Skyler JS, Bakris GL, Bonifacio E, et al. Differentiation of diabetes by pathophysiology, natural history, and prognosis. Diabetes. 2017;66(2):241–255. doi:10.2337/db16-0806
   PubMed Web of Science ®Google Scholar
• Lyons TJ, Basu A. Biomarkers in diabetes: hemoglobin A1c, vascular and tissue markers. Transl Res. 2012;159(4):303–312. doi:10.1016/j.trsl.2012.01.009
   PubMed Web of Science ®Google Scholar
• Diwaker A, Kishore D, Singh V, Mahapatra SP. The novel biomarkers in diabetes. J Assoc Physicians India. 2019;67(7):65–69.
   PubMedGoogle Scholar
• Punthakee Z, Goldenberg R, Katz P. Définition, classification et diagnostic du diabète, du prédiabète et du syndrome métabolique. Can J Diabetes. 2018;42:S10–S15. doi:10.1016/j.jcjd.2017.10.003
   PubMed Web of Science ®Google Scholar
• Riaz S. Study of protein biomarkers of diabetes mellitus type 2 and therapy with vitamin B1. J Diabetes Res. 2015;2015:1–10. doi:10.1155/2015/150176
   Web of Science ®Google Scholar
• Yimer EM, Zewdie KA, Hishe HZ. Netrin as a novel biomarker and its therapeutic implications in diabetes mellitus and diabetes-associated complications. J Diabetes Res. 2018;2018:1–20. doi:10.1155/2018/8250521
   Web of Science ®Google Scholar
• Laakso M. Biomarkers for type 2 diabetes. Mol Metab. 2019;27:S139–S146. doi:10.1016/j.molmet.2019.06.016
   Web of Science ®Google Scholar
• Lu B, Zhao M, Jiang W, et al. Independent association of circulating level of chemerin with functional and early morphological vascular changes in newly diagnosed type 2 diabetic patients. Medicine. 2015;94(47):1–8. doi:10.1097/MD.0000000000001990
   Google Scholar
• Mamdouh M, Shaban S, Ibrahim Abushouk A, Zaki MMM, Ahmed OM, Abdel-Daim MM. Adipokines: potential therapeutic targets for vascular dysfunction in type II diabetes mellitus and obesity. J Diabetes Res. 2017;2017:1–11.
   Google Scholar
• Blüher M. Adipokines–removing road blocks to obesity and diabetes therapy. Mol Metab. 2014;3(3):230–240. doi:10.1016/j.molmet.2014.01.005
   PubMed Web of Science ®Google Scholar
• Tilg H, Moschen AR. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol. 2006;6(10):772–783. doi:10.1038/nri1937
   PubMed Web of Science ®Google Scholar
• Blüher M. Clinical relevance of adipokines. Diabetes Metab J. 2012;36(5):317–327. doi:10.4093/dmj.2012.36.5.317
   PubMedGoogle Scholar
• Freitas Lima LC, Braga V, Do Socorro de França Silva M, et al. Adipokines, diabetes and atherosclerosis: an inflammatory association. Front Physiol. 2015;6:304. doi:10.3389/fphys.2015.00304
   PubMed Web of Science ®Google Scholar
• Cook KS, Groves DL, Min HY, Spiegelman BM. A developmentally regulated mRNA from 3T3 adipocytes encodes a novel serine protease homologue. Proc Natl Acad Sci. 1985;82(19):6480–6484. doi:10.1073/pnas.82.19.6480
   PubMedGoogle Scholar
• Zhou Q, Ge Q, Ding Y, et al. Relationship between serum adipsin and the first phase of glucose‐stimulated insulin secretion in individuals with different glucose tolerance. J Diabetes Investig. 2018;9(5):1128–1134. doi:10.1111/jdi.12819
   PubMedGoogle Scholar
• Lo JC, Ljubicic S, Leibiger B, et al. Adipsin is an adipokine that improves β cell function in diabetes. Cell. 2014;158(1):41–53. doi:10.1016/j.cell.2014.06.005
   PubMed Web of Science ®Google Scholar
• Gómez-Banoy N, Guseh JS, Li G, et al. Adipsin preserves beta cells in diabetic mice and associates with protection from type 2 diabetes in humans. Nat Med. 2019;25(11):1739–1747. doi:10.1038/s41591-019-0610-4
   PubMed Web of Science ®Google Scholar
• Baas T. Adipsin meets β cells. Sci Bus Exch. 2014;7(30):883–886. doi:10.1038/scibx.2014.883
   Google Scholar
• Song N-J, Kim S, Jang B-H, et al. Small molecule-induced complement factor D (Adipsin) promotes lipid accumulation and adipocyte differentiation. PLoS One. 2016;11(9):e0162228. doi:10.1371/journal.pone.0162228
   PubMedGoogle Scholar
• Legakis I, Mantzouridis T, Bouboulis G, Chrousos GP. Reciprocal changes of serum adispin and visfatin levels in patients with type 2 diabetes after an overnight fast. Arch Endocrinol Metab. 2016;60(1):76–78. doi:10.1590/2359-3997000000147
   PubMedGoogle Scholar
• Karajibani M, Montazerifar F, Sadeghi MB, Keikhaie MA, Dashipour A. Serum fetuin-A and adipsin levels in type II diabetes patients. Int J High Risk Behav Addict. 2019;1–6.
   Google Scholar
• Wang J-S, Lee W-J, Lee I-T, et al. Association between serum Adipsin levels and insulin resistance in subjects with various degrees of glucose intolerance. J Endocr Soc. 2019;3(2):403–410. doi:10.1210/js.2018-00359
   PubMedGoogle Scholar
• Vasilenko MA, Kirienkova EV, Skuratovskaia DA, et al., editors. The role of production of adipsin and leptin in the development of insulin resistance in patients with abdominal obesity. Dokl Biochem Biophys. 2017;475:271–276. doi:10.1134/S160767291704010X
   PubMedGoogle Scholar
• Kumar NP, Nair D, Banurekha V, et al. Type 2 diabetes mellitus coincident with pulmonary or latent tuberculosis results in modulation of adipocytokines. Cytokine. 2016;79:74–81. doi:10.1016/j.cyto.2015.12.026
   PubMedGoogle Scholar
• Taşdemir E, Şermet A. The relationship between plasma adipsin, adiponectin, vaspin, visfatin, and leptin levels with glucose metabolism and diabetes parameters. Haydarpasa Numune Med J. 2019;59(2):95–103.
   Google Scholar
• Klimontov VV, Bulumbaeva DM, Bgatova NP, et al. Serum adipokine concentrations in patients with type 2 diabetes: the relationships with distribution, hypertrophy and vascularization of subcutaneous adipose tissue. Diabetes mellitus. 2019;22(4):336–347. doi:10.14341/DM10129
   Google Scholar
• Cox AJ, Zhang P, Bowden DW, et al. Enteroendocrine and adipokine associations with type 2 diabetes: phenotypic risk scoring approaches. J Gastroenterol Hepatol. 2018;33(7):1357–1364. doi:10.1111/jgh.14057
   PubMedGoogle Scholar
• Derosa G, Fogari E, D’Angelo A, et al. Adipocytokine levels in obese and non-obese subjects: an observational study. Inflammation. 2013;36(4):914–920. doi:10.1007/s10753-013-9620-4
   PubMed Web of Science ®Google Scholar
• Azizi M, Tadibi V, Behpour N. The effect of aerobic exercise training on β-cell function and circulating levels of adipsin in community of obese women with type 2 diabetes mellitus. Int J Diabetes Dev Ctries. 2017;37(3):298–304. doi:10.1007/s13410-016-0504-7
   Google Scholar